Further insights into to the role of statins against active tuberculosis: systematic review and meta-analysis.

E. Meregildo-Rodriguez, Eleodoro Vladimir Chunga-Chévez, Robles-Arce Luis Gianmarco, G. Vásquez-Tirado
{"title":"Further insights into to the role of statins against active tuberculosis: systematic review and meta-analysis.","authors":"E. Meregildo-Rodriguez, Eleodoro Vladimir Chunga-Chévez, Robles-Arce Luis Gianmarco, G. Vásquez-Tirado","doi":"10.53854/liim-3002-4","DOIUrl":null,"url":null,"abstract":"Objectives Tuberculosis is a major cause of global morbidity and mortality. Statins could be associated with a lower risk of some infectious diseases, including tuberculosis. Statins could reduce the risk of latent tuberculosis infection and active tuberculosis, acting as an adjuvant in treating tuberculosis. This study aimed to determine if statins reduce the risk of active tuberculosis. Methods We systematically analyzed 8 databases from inception to December 2021. We included articles without language restriction if they met our inclusion and exclusion criteria and the PECO strategy (Population: adults without active pulmonary tuberculosis; Exposure: treatment with any statin; Comparator: no use of statins; Outcome: active tuberculosis). Odds Ratios (ORs) with 95% confidence intervals (CIs) were pooled using random- effects models regardless of heterogeneity quantified by Cochran's Q and I2 statistics. We performed subgroup analyses according to the participants' diabetic status and follow-up length (≤10 years or >10 years). Results Twelve articles reporting observational studies involving 3.038.043 participants, including at least 32.668 cases of active tuberculosis. Eight reported retrospective cohort studies, three nested case-control study, and one was a case control study.According to our meta-analysis, statins may reduce the risk of active tuberculosis, in the general population (OR 0.66; 95% CI, 0.54-0.81), in non-diabetic (OR 0.66; 95% CI, 0.54-0.80) and in diabetic patients (OR 0.65; 95% CI, 0.49-0.87). This protective effect did not differ according to the participants' diabetic status nor follow-up length (test for subgroup differences I2=0). We found significant clinical and methodological heterogeneity. Similarly, the forest plot, and the I2 and Chi2 statistics suggested considerable statistical heterogeneity (I2=95%, p<0.05, respectively). Of the 12 included studies, 9 were at low risk of bias and 3 were at high risk of bias. Similarly, according to the funnel plot, it is very likely that there are important publication biases. Conclusion Statin use may significantly reduce the risk of tuberculosis in the general population, diabetic and non-diabetic patients. Nevertheless, caution should be exercised when interpreting these conclusions, due to the quality of the evidence, the heterogeneity of the studies, the presence of bias, and the difficulty in extrapolating these results to populations of other races and ethnicities.","PeriodicalId":17977,"journal":{"name":"Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53854/liim-3002-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Objectives Tuberculosis is a major cause of global morbidity and mortality. Statins could be associated with a lower risk of some infectious diseases, including tuberculosis. Statins could reduce the risk of latent tuberculosis infection and active tuberculosis, acting as an adjuvant in treating tuberculosis. This study aimed to determine if statins reduce the risk of active tuberculosis. Methods We systematically analyzed 8 databases from inception to December 2021. We included articles without language restriction if they met our inclusion and exclusion criteria and the PECO strategy (Population: adults without active pulmonary tuberculosis; Exposure: treatment with any statin; Comparator: no use of statins; Outcome: active tuberculosis). Odds Ratios (ORs) with 95% confidence intervals (CIs) were pooled using random- effects models regardless of heterogeneity quantified by Cochran's Q and I2 statistics. We performed subgroup analyses according to the participants' diabetic status and follow-up length (≤10 years or >10 years). Results Twelve articles reporting observational studies involving 3.038.043 participants, including at least 32.668 cases of active tuberculosis. Eight reported retrospective cohort studies, three nested case-control study, and one was a case control study.According to our meta-analysis, statins may reduce the risk of active tuberculosis, in the general population (OR 0.66; 95% CI, 0.54-0.81), in non-diabetic (OR 0.66; 95% CI, 0.54-0.80) and in diabetic patients (OR 0.65; 95% CI, 0.49-0.87). This protective effect did not differ according to the participants' diabetic status nor follow-up length (test for subgroup differences I2=0). We found significant clinical and methodological heterogeneity. Similarly, the forest plot, and the I2 and Chi2 statistics suggested considerable statistical heterogeneity (I2=95%, p<0.05, respectively). Of the 12 included studies, 9 were at low risk of bias and 3 were at high risk of bias. Similarly, according to the funnel plot, it is very likely that there are important publication biases. Conclusion Statin use may significantly reduce the risk of tuberculosis in the general population, diabetic and non-diabetic patients. Nevertheless, caution should be exercised when interpreting these conclusions, due to the quality of the evidence, the heterogeneity of the studies, the presence of bias, and the difficulty in extrapolating these results to populations of other races and ethnicities.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
进一步了解他汀类药物对活动性结核病的作用:系统回顾和荟萃分析。
目的结核病是全球发病率和死亡率的主要原因。他汀类药物可以降低患某些传染病的风险,包括结核病。他汀类药物可以降低潜伏性结核病感染和活动性结核病的风险,作为治疗结核病的辅助药物。本研究旨在确定他汀类药物是否能降低活动性结核病的风险。方法系统分析8个数据库自成立至2021年12月的数据。我们纳入了符合纳入和排除标准以及PECO策略的无语言限制的文章(人群:无活动性肺结核的成年人;暴露:任何他汀类药物治疗;比较者:未使用他汀类药物;结果:活动性肺结核)。使用随机效应模型合并95%置信区间(ci)的比值比(ORs),而不考虑Cochran's Q和I2统计量化的异质性。我们根据参与者的糖尿病状态和随访时间(≤10年或>10年)进行亚组分析。结果纳入12篇观察性研究,涉及3,038.043名受试者,包括至少32.668例活动性结核病。8项回顾性队列研究,3项巢式病例对照研究,1项病例对照研究。根据我们的荟萃分析,在普通人群中,他汀类药物可以降低活动性结核病的风险(OR 0.66;95% CI, 0.54-0.81),非糖尿病患者(OR 0.66;95% CI, 0.54-0.80)和糖尿病患者(OR 0.65;95% ci, 0.49-0.87)。这种保护作用不因参与者的糖尿病状态和随访时间而异(亚组差异测试I2=0)。我们发现了显著的临床和方法学异质性。同样,森林样地、I2和Chi2的统计也显示出相当大的统计异质性(I2=95%, p<0.05)。在纳入的12项研究中,9项为低偏倚风险,3项为高偏倚风险。同样,根据漏斗图,很可能存在重要的发表偏倚。结论他汀类药物可显著降低普通人群、糖尿病患者和非糖尿病患者结核病的发生风险。然而,由于证据的质量、研究的异质性、偏见的存在,以及将这些结果外推到其他种族和民族人群的困难,在解释这些结论时应谨慎。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Real-life use of remdesivir-containing regimens in COVID-19: a retrospective case-control study. The prevalence of gonococcal and non-gonococcal infections in women referred to obstetrics and gynecology clinics. Impact of COVID-19 severity on health-related quality of life among Saudi adult patients. Postbiotics as the key mediators of the gut microbiota-host interactions. Rhino-orbito-cerebral mucormycosis in an acute lymphoblastic leukemia pediatric patient. Case report and review of literature.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1